when you are looking for knowledgeable people go withe the white girl and the italian

insulin was a life sabing disvovery but faudtmsn snd ristori address more than its immunological shortcomings and futility

see faustmanlab.org
pubmed.org faustman dl

pubmed.org ristori + bcg
uspto.gov inventor search faustman

Review

. 2018 Dec;55:89-96.

doi: 10.1016/j.coi.2018.09.016.Epub 2018 Nov 15.

Bridging the Gap Between Vaccination With Bacille Calmette-Guérin (BCG) and Immunological Tolerance: The Cases of Type 1 Diabetes and Multiple Sclerosis

Giovanni Ristori 1, Denise Faustman 2, Giuseppe Matarese 3, Silvia Romano 4, Marco Salvetti 5

Affiliations

PMID: 30447407
DOI: 10.1016/j.coi.2018.09.016

Abstract

At the end of past century, when the prevailing view was that treatment of autoimmunity required immune suppression, experimental evidence suggested an approach of immune-stimulation such as with the BCG vaccine in type 1 diabetes (T1D) and multiple sclerosis (MS). Translating these basic studies into clinical trials, we showed the following: BCG harnessed the immune system to 'permanently' lower blood sugar, even in advanced T1D; BCG appeared to delay the disease progression in early MS; the effects were long-lasting (years after vaccination) in both diseases. The recently demonstrated capacity of BCG to boost glycolysis may explain both the improvement of metabolic indexes in T1D, and the more efficient generation of inducible regulatory T cells, which counteract the autoimmune attack and foster repair mechanisms.

Trump Unveils Plan To Cap Insulin Costs For Seniors, Takes Jabs At Biden for not reading pubmed.org faustman dl, pubmed.org ristori + bcg

May 26, 20206:24 PM ET

AYESHA RASCOE

Twitter

President Trump delivers remarks on lowering insulin costs for seniors with diabetes on Thursday at the White House.

Brendan Smialowski/AFP via Getty Images

Seniors with diabetes will be able to sign up for Medicare plans that cap their co-payments for insulin at $35 a month beginning next year, the White House announced on Tuesday.

The news comes as some polls show Trump's support slipping with seniors, a voting bloc that may play a pivotal role in the November election. In 2016, he won over older voters, but recent polls show him trailing Democratic challenger Joe Biden.

The new options for reducing insulin costs are the result of an agreement reached by the Trump administration with insulin manufacturers and major insurance companies.

"This is a big day for seniors," President Trump said in a Rose Garden speech where he took the opportunity to take several direct swings at Biden over health care issues.

"We brought all of the parties to the table — insurers, manufacturers, and other key players — and reached an agreement to deliver insulin at stable and drastically lower out-of-pocket cost for our seniors. I hope the seniors are going to remember it, because Biden is the one that put us into the jam, because they didn't know what they were doing," Trump said.

Trump has long pledged to take action to lower prescription drug costs, but has failed to forge common ground with Congress on the issue. Democrats passed a bill in the House of Representatives last year that would see the government negotiate prices for expensive drugs, pegged to costs in other countries.

Some Senate Republicans have backed a more modest plan to limit Medicare prescription costs, but others in Trump's party oppose interfering in the market.

More than 3 million people on Medicare use insulin to control their diabetes, according to the White House.

Seema Verma, who heads the Centers for Medicare and Medicaid Services, said plans that offer the insulin cap will have more expensive premiums, costing about $17 more per month than the average cost of basic plans.

"In exchange for a minimal premium increase, beneficiaries get a maximum fixed $35 co-pay for a month's supply of insulin," Verma said on a call with reporters. She said that ultimately seniors will save 66% on their insulin costs.

Verma said that if the deal capping costs on insulin is successful, the administration will attempt to take similar action with other expensive drugs.